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a cost savings of $21,200 per year in 41 patients with
Type 2 diabetes. CONCLUSION: Control of diabetes as
measured by the HbA1c was signiﬁcantly better after 
the initiation of insulin glargine with beneﬁts including a
decreased overall frequency of hypoglycemia. Addition-
ally, insulin glargine may be a cost-effective alternative 
to increases in the dose or number of oral hypoglycemic
agents in patients with Type 2 diabetes. Conclusive evi-
dence on the efﬁcacy of insulin glargine will come from
larger cohort studies.
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OBTAINING QUALITY REAL-WORLD
TREATMENT DATA FOR ECONOMIC 
MODELS: METHODOLOGY AND RESULTS 
OF A WOUND CARE MEDICAL RECORD
ABSTRACTION STUDY
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OBJECTIVES: Although clinical trial data are often used
in economic models, they may not reﬂect real-world 
utilization and outcomes of therapy. To determine real-
world resource use and outcomes of diabetic foot ulcer
(DFU) care using Graftskin (a living bi-layered skin sub-
stitute) and to supplement clinical data for a DFU treat-
ment model, a medical record abstraction study was
conducted at 21 U.S. treatment centers that practice good
wound care (GWC). METHODS: Two physician samples
were recruited: a Graftskin sample (physicians who fre-
quently use and receive reimbursement for Graftskin 
in the treatment of DFUs), and a non-Graftskin sample
(physicians who treat DFU using GWC and who do not
receive reimbursement for using Graftskin). Separate
abstraction forms were developed for each sample, sent
by mail to the treatment centers, completed by center
staff, and returned via fax. The center received a small
honorarium per completed form. RESULTS: Twenty-one
centers and 166 cases (83 Graftskin and 83 GWC) were
included in the analysis. Graftskin patients had more
severe DFUs (21cm2) than those in the Graftskin pivotal
trial (2.97cm2), which compared GWC plus Graftskin to
GWC alone. In addition, Graftskin patients had more
severe DFUs than the GWC patients in this study 
(11cm2). The mean number of Graftskin applications was
much lower in this study (1.27 applications) than in the
Graftskin pivotal trial (3.9 applications). Moreover, in
this study, the incidence of severe adverse events was sig-
niﬁcantly lower with Graftskin (37%) than with GWC
(52%), even when controlling for ulcer severity (p =
0.006). CONCLUSION: In actual practice, the number
of Graftskin applications was considerably lower and
DFU severity was substantially higher than in the 
Graftskin pivotal clinical trial. These data were applied
to the DFU treatment model, which yielded improved
estimates of the real-world impact of utilizing Graftskin
versus GWC.
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OBJECTIVES: Medication adherence and compliance are
problems in young and elderly patients. With the increas-
ing number of prescribed drugs, compliance drops and
the number of adverse events increases. Furthermore,
elderly patients are likely to have several co-morbidities,
which could also affect their drug-consumption behavior
considerably. In this study, our objective was to evaluate
the compliance of anti-diabetic medication therapy in
subjects with type 2 diabetes mellitus who initiated treat-
ment with one of various oral anti-diabetic drugs or
insulin. METHODS: Data for this study spanned the
period January 1, 1995 to March 31, 2002 and were
obtained from the Pharmetrics Patient-Centric Database,
which is comprised of fully adjudicated medical and phar-
maceutical claims for over 29 million unique patients
from 52 health plans across the US. Patients with Type 2
diabetes mellitus (n = 199,000) were classiﬁed into mutu-
ally exclusive treatment groups based on the therapy ﬁrst
received during the period of observation. Compliance
rate was determined by the total number of days between
ﬁrst ﬁlled and last ﬁlled prescription plus days ﬁlled in the
last prescription, divided by last ﬁll date and the ﬁrst ﬁll
date plus a 90-day gap. RESULTS: The pioglitazone
group (n = 2,730) ranked the highest in compliance with
a mean of 85% (89% in the 55–64 age group) and a
median of 91% compared to a mean compliance of 62%
in the insulin group (n = 27,274) (P < 0.001) and 81% in
the metformin group (n = 52,469) (P = 0.001). Similar
results were found in newly diagnosed subjects. One-third
of all pioglitazone patients added a second line therapy
for diabetes compared to 43.9% on rosiglitazone (n =
4,068). CONCLUSION: Compliance to treatment
regimen for patients taking pioglitazone was higher than
for patients on other anti-diabetic medications.
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OBJECTIVES: Patient risk is identiﬁed by an increase in
healthcare cost, the occurrence of hospitalization or emer-
gency room (ER) event, and a decrease in time to hospi-
talization or ER event. The purpose of this research is 
to investigate factors associated with high-risk diabetic
patients based on claims data from the California Med-
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icaid (MediCal) program. METHODS: A retrospective
study was conducted by using claims data from January
1995 to December 2000. Dependent variables were total
healthcare cost, the occurrence of event, and time to
event. Event included hospitalization or ER visits. His-
torical data including demographic factors, healthcare
cost and utilization, type of drugs, increasing dose,
adding drugs, changing drugs, follow-up services based
on diabetic guidelines (e.g., ofﬁce visit, lab tests, and self
glucose monitoring), medication compliance, complica-
tions, and comorbidity were used as independent vari-
ables. The generalized estimating equation and the ﬁxed
effect partial likelihood methods were used in a longitu-
dinal data set and a cross-sectional data set with repeat-
able events, respectively. RESULTS: Older age was related
to an increase in patient risk. Healthcare cost and uti-
lization in the previous period had a signiﬁcant positive
impact on patient risk in the next period. Patients taking
both insulin and oral hypoglycemic drugs and patients
having oral hypoglycemic or anti-hypertensive drugs
added into the regimen were positively associated with an
increase in patient risk. However, medication compliance
was negatively related to an increase in patient risk.
Follow-up services based on diabetic guidelines factors
(i.e., having ofﬁce visit, having glucose monitoring strip,
having HbA1C test) were negatively associated with an
increase in patient risk. Comorbidity factors (i.e., hyper-
tension and hyperlipidemia) and three complication
factors (i.e., retinopathy, nephropathy and foot infection)
were positively related to patient risk. CONCLUSIONS:
Factors associated with high-risk diabetic patients could
help healthcare providers and administrators intervene to
improve patient outcomes.
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OBJECTIVES: There is increasing concern that rising
drug costs may make prescription drugs unaffordable to
seniors and therefore a need for Medicare prescription
beneﬁts coverage. The objective of this study was to assess
prescription drug use patterns and expenditure of diabetic
Medicare beneﬁciaries with supplemental private insur-
ance with and without prescription beneﬁts. METHODS:
The 1999 Medical Expenditure Panel Survey (MEPS) pro-
vided the data for the study. Medicare diabetics with sup-
plemental private insurance coverage were identiﬁed, and
those with and without prescription beneﬁts separated
into two groups. Descriptive statistics for the two groups
were determined and t-test used to compare differences
in age, education, income, number of diabetes related pre-
scriptions, total drug and out of pocket drug expenditures
related to diabetes, and number of comorbidities.
RESULTS: A total of 453 Medicare diabetics were iden-
tiﬁed from a total of 24,618 MEPS respondents with 186
(39.4%) reporting supplemental private insurance. Of
these, 103 (55.4%) reported drug coverage. Those with
and without drug coverage did not differ signiﬁcantly
with respect to age but education was signiﬁcantly dif-
ferent (p = 0.04) with those having coverage being more
educated. Income differed but did not reach statistical sig-
niﬁcance (p = 0.053). The two cohorts did not differ sig-
niﬁcantly in terms of total number of diabetes-related
prescriptions and both total and out of pocket expendi-
tures. However, out of pocket cost for those without 
prescription coverage averaged about 76% of total drug
expenditure while it averaged 53% for those with cover-
age. CONCLUSIONS: In the MEPS data, Medicare dia-
betics with supplemental private insurance coverage with
and without prescription beneﬁts did not differ in terms
of diabetes related prescription use and expenditure.
However, those with out drug coverage who had a lesser
mean income ($15,670) incurred a higher percentage of
out of pocket drug cost than those with coverage and who
had a higher mean income ($19,199).
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